Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | June 12, 2025 | June 16, 2025 |
| Clearside Biomedical, Inc.CLSD · Entity 82875 | Director | June 20, 2024 | June 21, 2024 |
| Endo International plcENDP · Entity 124463 | Director | June 11, 2021 | June 15, 2021 |
| PhaseBio Pharmaceuticals IncPHAS · Entity 113305 | Director | May 19, 2023 | May 19, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date June 12, 2025 · Filed June 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 99,138 |
Reported balance
After 2025-06-12 transaction · row 1
1 source rowRow 1 · 2025-06-12 · Grant · Acquired 12,500 · Balance 99,138 F1: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. |
| Automatic Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $10.40 · Expires 2035-06-12 | Direct | 27,181 |
Reported balance
After 2025-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-12 · Grant · Acquired 27,181 · Balance 27,181 F2: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
F2: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.
Clearside Biomedical, Inc.
Report date June 20, 2024 · Filed June 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2034-06-19 | Direct | 45,000 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 45,000 · Balance 45,000 F1: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2025, subject to the Reporting Person's continuous service as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2025, subject to the Reporting Person's continuous service as of such vesting date.
Endo International plc
Report date June 11, 2021 · Filed June 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 116,140 |
Ending reported balance
After 2021-06-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-06-11 · Grant · Acquired 47,924 · Balance 139,143 F1: These ordinary shares were granted to Dr. Hutson on June 11, 2021 in consideration of her services on Endo International plc's Board of Directors. Row 2 · 2021-06-11 · Tax withholding · Disposed 23,003 · Balance 116,140 F2: These shares represent ordinary shares withheld by Endo International plc to satisfy Dr. Hutson's tax withholding obligations on shares acquired on June 11, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: These ordinary shares were granted to Dr. Hutson on June 11, 2021 in consideration of her services on Endo International plc's Board of Directors.
F2: These shares represent ordinary shares withheld by Endo International plc to satisfy Dr. Hutson's tax withholding obligations on shares acquired on June 11, 2021.
PhaseBio Pharmaceuticals Inc
Report date May 19, 2023 · Filed May 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,510 |
Reported balance
After 2023-05-19 transaction · row 1
1 source rowRow 1 · 2023-05-19 · Exercise / conversion · Acquired 3,750 · Balance 37,510 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-05-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-05-19 · Exercise / conversion · Disposed 3,750 · Balance 0 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. F2: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date. |
| Common StockSEC Table I · non-derivative | IndirectHeld in an individual retirement account for the benefit of the Reporting Person | 4,000 |
Reported balance
Holding disclosure · report date 2023-05-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock.
F2: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2025 Filed Jun 16, 2025 20:20 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 27,181 | $0.00 Strike: $10.40 | $0.00 |
DisclosureSEC source: 0001171843-25-003914 · ownership.xml · derivative · entry 2 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,181 Underlying: Common Stock · 27,181 shares Expires 2035-06-12 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:20 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-003914 · ownership.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,138 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| December 13, 2024 Filed Dec 16, 2024 21:35 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 7,000 | $7.54 | $52,780.00 |
DisclosureSEC source: 0001127602-24-029494 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,638 F1 · shares: These shares were sold pursuant to a plan adopted by the Reporting Person on June 18, 2024 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, for the sole purpose of generating sufficient proceeds to cover the tax liability incurred in connection with the vesting of 16,745 restricted stock units. The sale occurred automatically and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.510 to $7.565. The Reporting Person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 16:15 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001415889-24-017825 · form4-06212024_040614.xml · derivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 20, 2025, subject to the Reporting Person's continuous service as of such vesting date. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:27 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 49,933 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001127602-24-018720 · form4.xml · derivative · entry 2 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,933 Underlying: Common Stock · 49,933 shares Expires 2034-06-12 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:27 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 6,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-018720 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,638 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| May 20, 2024 Filed May 22, 2024 11:24 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | PurchaseCommon Stock | 5,000 | $6.38 | $31,900.00 |
DisclosureSEC source: 0001127602-24-016190 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,818 F1 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $6.375 to $6.38. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| October 03, 2023 Filed Oct 4, 2023 17:06 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | PurchaseCommon Stock | 10,000 | $0.86 | $8,600.00 |
DisclosureSEC source: 0001209191-23-052027 · doc4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,000 Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 16:38 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001209191-23-039419 · doc4.xml · derivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 22, 2024, subject to the Reporting Person's continuous service as of such vesting date. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 20:33 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 12,866 | $8.04 | $103,442.64 |
DisclosureSEC source: 0001127602-23-018775 · form4.xml · nonDerivative · entry 2 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,818 F2 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $7.89 to $8.12. The reporting person will provide to the issuer, or any security holder of the issuer, or the SEC staff upon request, full information regarding the number of shares purchased at each price within the range set forth in the footnote. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:33 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 39,072 | $0.00 Strike: $8.18 | $0.00 |
DisclosureSEC source: 0001127602-23-018775 · form4.xml · derivative · entry 3 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,072 Underlying: Common Stock · 39,072 shares Expires 2033-06-13 F3 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:33 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 16,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-018775 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,684 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| May 19, 2023 Filed May 19, 2023 16:15 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001169245-23-000027 · wf-form4_168452733692556.xml · derivative · entry 3 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. F2 · derivative.exercise_date: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date. F2 · derivative.expiration_date: The RSUs vested and were delivered to the Reporting Person on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 19, 2023 Filed May 19, 2023 16:15 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001169245-23-000027 · wf-form4_168452733692556.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 08:12 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | PurchaseCommon Stock | 30,000 | $1.33 | $39,900.00 |
DisclosureSEC source: 0001209191-22-058025 · doc4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.31 to $1.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 16:25 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001209191-22-039233 · doc4.xml · derivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-06-21 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 22, 2023. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:48 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 30,022 | $0.00 Strike: $10.79 | $0.00 |
DisclosureSEC source: 0001127602-22-017163 · form4.xml · derivative · entry 2 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,022 Underlying: Common Stock · 30,022 shares Expires 2032-06-07 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:48 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 12,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-017163 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,939 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| May 19, 2022 Filed May 20, 2022 16:45 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantRestricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001169245-22-000064 · wf-form4_165307952529586.xml · derivative · entry 2 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. F3 · derivative.exercise_date: The RSUs shall vest and be delivered to the Reporting Person on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date. F3 · derivative.expiration_date: The RSUs shall vest and be delivered to the Reporting Person on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 19, 2022 Filed May 20, 2022 16:45 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | GrantNon-employee Director Stock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001169245-22-000064 · wf-form4_165307952529586.xml · derivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2032-05-18 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date. Read SEC document |
| November 08, 2021 Filed Nov 8, 2021 18:26 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | Exercise / conversionNon-employee Director Stock Option (right to buy) · Derivative | 7,400 | $3.15 Strike: $3.15 | $23,310.00 |
DisclosureSEC source: 0001169245-21-000106 · wf-form4_163641394792074.xml · derivative · entry 6 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,400 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option shall vest in equal monthly installments over 36 months from October 17, 2018, subject to the reporting person's continued service through each such date. Read SEC document |
| November 08, 2021 Filed Nov 8, 2021 18:26 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | Exercise / conversionCommon Stock | 7,400 | $3.15 | $23,310.00 |
DisclosureSEC source: 0001169245-21-000106 · wf-form4_163641394792074.xml · nonDerivative · entry 3 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,760 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2021 Filed Nov 8, 2021 18:26 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | Exercise / conversionNon-employee Director Stock Option (right to buy) · Derivative | 1,500 | $3.15 Strike: $3.15 | $4,725.00 |
DisclosureSEC source: 0001169245-21-000106 · wf-form4_163641394792074.xml · derivative · entry 5 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,400 Underlying: Common Stock · 1,500 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option shall vest in equal monthly installments over 36 months from October 17, 2018, subject to the reporting person's continued service through each such date. Read SEC document |
| November 05, 2021 Filed Nov 8, 2021 18:26 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | Exercise / conversionNon-employee Director Stock Option (right to buy) · Derivative | 24,860 | $2.26 Strike: $2.26 | $56,183.60 |
DisclosureSEC source: 0001169245-21-000106 · wf-form4_163641394792074.xml · derivative · entry 4 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,256 Underlying: Common Stock · 24,860 shares Expires 2028-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option shall vest with respect to 25% of the shares on February 21, 2019, and shall vest in 36 additional monthly installments thereafter, subject to the reporting person's continued service through each such date. Read SEC document |
| November 05, 2021 Filed Nov 8, 2021 18:26 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | Exercise / conversionCommon Stock | 1,500 | $3.15 | $4,725.00 |
DisclosureSEC source: 0001169245-21-000106 · wf-form4_163641394792074.xml · nonDerivative · entry 2 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,360 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2021 Filed Nov 8, 2021 18:26 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | Exercise / conversionCommon Stock | 24,860 | $2.26 | $56,183.60 |
DisclosureSEC source: 0001169245-21-000106 · wf-form4_163641394792074.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 16:40 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001209191-21-062427 · doc4.xml · derivative · entry 4 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-04-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option will vest and become exercisable in 36 equal monthly installments beginning on May 21, 2020, subject to the Reporting Person's continuous service as of such vesting dates. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 16:40 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001209191-21-062427 · doc4.xml · derivative · entry 3 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2030-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this option were fully vested as of June 18, 2021. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 16:40 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | Exercise / conversionCommon Stock | 15,000 | $2.09 | $31,350.00 |
DisclosureSEC source: 0001209191-21-062427 · doc4.xml · nonDerivative · entry 2 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 16:40 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | Exercise / conversionCommon Stock | 25,000 | $2.00 | $50,000.00 |
DisclosureSEC source: 0001209191-21-062427 · doc4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 20:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001127602-21-027342 · form4.xml · derivative · entry 9 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 20:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionAutomatic Stock Option Grant · Derivative | 15,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001127602-21-027342 · form4.xml · derivative · entry 8 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2023-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 20:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001127602-21-027342 · form4.xml · derivative · entry 7 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2027-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 20:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001127602-21-027342 · form4.xml · derivative · entry 6 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2029-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 20:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 105,000 | $15.40 | $1,617,000.00 |
DisclosureSEC source: 0001127602-21-027342 · form4.xml · nonDerivative · entry 5 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,073 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $15.13 to $15.51. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 20:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 30,000 | $3.22 | $96,600.00 |
DisclosureSEC source: 0001127602-21-027342 · form4.xml · nonDerivative · entry 4 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 20:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 15,000 | $1.71 | $25,650.00 |
DisclosureSEC source: 0001127602-21-027342 · form4.xml · nonDerivative · entry 3 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 20:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 30,000 | $5.13 | $153,900.00 |
DisclosureSEC source: 0001127602-21-027342 · form4.xml · nonDerivative · entry 2 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 20:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 30,000 | $2.91 | $87,300.00 |
DisclosureSEC source: 0001127602-21-027342 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021. Read SEC document |
| August 18, 2021 Filed Aug 19, 2021 16:24 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | PurchaseCommon Stock | 3,000 | $3.08 | $9,240.00 |
DisclosureSEC source: 0001169245-21-000083 · wf-form4_162940466260409.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held in an individual retirement account for the benefit of the reporting person Disclosed balance after: 4,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.07 to $3.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| August 18, 2021 Filed May 20, 2022 16:47 UTC Amendment | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | PurchaseCommon Stock | 3,000 | $3.08 | $9,240.00 |
DisclosureSEC source: 0001169245-22-000067 · wf-form4a_165307960124153.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held in an individual retirement account for the benefit of the Reporting Person Disclosed balance after: 4,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.07 to $3.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 16:39 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | PurchaseCommon Stock | 3,000 | $5.68 | $17,040.00 |
DisclosureSEC source: 0001209191-21-051883 · doc4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 16:06 UTC | Endo International plc ENDP · Entity 124463 | Tax withholdingOrdinary Shares | 23,003 | $6.26 | $143,998.78 |
DisclosureSEC source: 0001593034-21-000079 · wf-form4_162378753940214.xml · nonDerivative · entry 2 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,140 F2 · kind: These shares represent ordinary shares withheld by Endo International plc to satisfy Dr. Hutson's tax withholding obligations on shares acquired on June 11, 2021. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 16:06 UTC | Endo International plc ENDP · Entity 124463 | GrantOrdinary Shares | 47,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001593034-21-000079 · wf-form4_162378753940214.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,143 F1 · kind: These ordinary shares were granted to Dr. Hutson on June 11, 2021 in consideration of her services on Endo International plc's Board of Directors. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 17:40 UTC | Clearside Biomedical, Inc. CLSD · Entity 82875 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.11 | $0.00 |
DisclosureSEC source: 0001209191-21-039959 · doc4.xml · derivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: The shares underlying this option vest in full on the earlier of the Issuer's next annual meeting of stockholders or June 10, 2022. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:29 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionAutomatic Stock Option Grant · Derivative | 15,000 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0001127602-21-019792 · form4.xml · derivative · entry 5 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2022-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:29 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionNon-Qualified Stock Option · Derivative | 8,333 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001127602-21-019792 · form4.xml · derivative · entry 4 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,333 shares Expires 2022-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:29 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 23,333 | $16.86 | $393,394.38 |
DisclosureSEC source: 0001127602-21-019792 · form4.xml · nonDerivative · entry 3 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,073 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $16.76 to $17.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:29 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 15,000 | $3.32 | $49,800.00 |
DisclosureSEC source: 0001127602-21-019792 · form4.xml · nonDerivative · entry 2 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:29 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 8,333 | $2.85 | $23,749.05 |
DisclosureSEC source: 0001127602-21-019792 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.